Retatrutide, a novel dual activator of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) target, is demonstrating promising data in preliminary patient studies. Recent examination https://listbell.com/story11265937/retatrutide-emerging-studies-and-potential-medical-applications